Midatech Pharma (NASDAQ:MTP) Trading Up 2.3%

Midatech Pharma PLC-ADR (NASDAQ:MTP)’s stock price was up 2.3% on Friday . The stock traded as high as $1.32 and last traded at $1.32, approximately 1,002 shares changed hands during trading. A decline of 99% from the average daily volume of 115,693 shares. The stock had previously closed at $1.29.

Separately, ValuEngine raised Midatech Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

The company has a market cap of $3.98 million, a price-to-earnings ratio of -2.80 and a beta of 2.75. The company has a fifty day moving average price of $1.45 and a two-hundred day moving average price of $1.21. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.05.

A hedge fund recently bought a new stake in Midatech Pharma stock. Morgan Stanley purchased a new stake in Midatech Pharma PLC-ADR (NASDAQ:MTP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $72,000. Morgan Stanley owned approximately 1.63% of Midatech Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 17.42% of the company’s stock.

About Midatech Pharma (NASDAQ:MTP)

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.

See Also: What is the Gross Domestic Product (GDP)?

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.